CLINICAL TRACK

December 8, 2016

Session I-A: The Basics of IBD Patient Care
*Moderators: Raymond K. Cross, MD, MS, Douglas C. Wolf, MD*

12:20 pm What are the common mimics of ulcerative colitis and Crohn's disease?
Sunanda Kane, MD, MSPH
*Watch Presentation | View Slides*

12:40 pm Determination of disease severity
Corey A. Siegel, MD, MS
*Watch Presentation | View Slides*

1:00 pm Prevention of irreversible bowel damage in IBD
Jean-Frederic Colombel, MD
*Watch Presentation | View Slides*

1:20 pm Implementing treatment pathways for the management of ulcerative colitis and Crohn's disease: What are flow algorithms and how can we use them in our practice?
David T. Rubin, MD
*Watch Presentation | View Slides*

Session II-A: Current Therapeutic Approaches for the Optimal Medical Management of IBD
*Moderators: Russell Cohen, MD, Uma Mahadevan, MD*

2:20 pm First line therapies for ulcerative colitis and Crohn's disease
Douglas C. Wolf, MD
*Watch Presentation | View Slides*

2:40 pm Positioning immunomodulators as monotherapies or in combination with biologics
Gil Y. Melmed, MD
*Watch Presentation | View Slides*

3:00 pm How to induce and maintain remission using biologics
Gary R. Lichtenstein, MD
*Watch Presentation | View Slides*
3:20 pm  A practical guide for the use of therapeutic drug monitoring
Adam S. Cheifetz, MD

3:40 pm  What will be the hot IBD clinical topics in 2017?
Miguel Regueiro, MD

Session III-A: Monitoring and Managing Adverse Events Due to Immunomodulators and Biologics
Moderators: Jean-Federic Colombel, MD, Sunanda Kane, MD, MSPH

4:40 pm  Diagnosis and management of common dermatologic problems in our IBD patients
Mille Long, MD, MPH

5:00 pm  Putting neoplasia risks attributed to immunomodulators and biologics into perspective and what to do if a malignancy develops
James D. Lewis, MD, MSCE

5:20 pm  Neurologic, rheumatologic, and optic complications related to immunomodulators and biologic
Raymond K. Cross, MD, MS

5:40 pm  Diagnosis and management of infections in IBD patients on immunomodulators and biologics
Edward V. Loftus, MD

6:00 pm  Health maintenance in IBD: Prevention of infectious diseases due to immunosuppression
Francis A. Farraye, MD, MS

December 9, 2016

Session IV-A: Emerging Therapies for IBD
Moderators: Gary R. Lichtenstein, MD, David T. Rubin, MD

8:20 am  Understanding the mechanisms of action of new agents: Implications for efficacy and safety
Bruce E. Sands, MD, MS
8:40 am  Positioning current and future anti-integrin therapies for IBD
Brian Feagan, MD

9:00 am  How will we use ustekinumab and new therapies that target the IL-12/23 pathway in IBD?
William J. Sandborn, MD

9:20 am  How will future therapeutic pathways change for ulcerative colitis and Crohn's disease?
Stephen B. Hanauer, MD

Session Track V-A: Challenges in IBD: Case discussions
Moderators: Miguel Regueiro, MD, Corey A. Siegel, MD, MS

10:30 am Case Discussion I: Which biologic is best, which one should be started first, and how to decide?
Panelists: Jean-Federic Colombel, MD, Asher Kornbluth, MD, William J. Sandborn, MD

11:00 am Case Discussion II: When to optimize, stop, or switch biologics and immunomodulators?
Panelists: Gary R. Lichtenstein, MD, David T. Rubin, MD, Bruce E. Sands, MD, MS

11:30 am Case Discussion III: Perspectives on the use of biosimilars in IBD: The good, the bad, and the ugly
Panelists: Adam S. Cheifetz, MD, Brian Feagan, MD, Stephen B. Hanauer, MD

12:00 pm Case Discussion IV: How can we best approach pregnancy in ulcerative colitis and Crohn's disease patients?
Panelists: Sunanda Kane, MD, MSPH, Millie Long, MD, MPH, Uma Mahadevan, MD

Session VI-A: Case-based Clinical Breakout Sessions

2:00 & 3:00 pm  A. Treating the outpatient with moderate to severe ulcerative colitis, who has lost response to their first biologic: Case studies
Leonard K. Baidoo, MD, Peter D. Higgins, MD, PhD, MSc, Uma Mahadevan, MD

B. Sexual dysfunction in male and female IBD patients: Case studies
Raymond K. Cross, MD, Marla Dubinsky, MD, Kim L. Isaacs, MD, PhD
C. Challenges in decision making, for the surgical management of Crohn's colitis and Crohn's proctocolitis: Case studies
Philip Fleshner, MD, Feza H. Remzi, MD, Bo Shen, MD

D. Controversies in surveillance for colorectal cancer in IBD: Case studies
Meenakshi Bewtra, MD, PhD, MPH, Thomas Ullman, MD, Fernando S. Velayos, MD, MPH

E. New models of care for IBD: The patient centered medical home and increasing patient engagement: Case studies
Miguel Regueiro, MD, Eva Szigethy, MD, PhD, Corey A. Siegel, MD, MS

Session VII-A: Surgery and IBD: What Surgeons Want Gastroenterologists to Know
Moderators: Philip R. Fleshner, MD, Gil Y. Melmed, MD, Feza H. Remzi, MD

4:00 pm  Preoperative optimization and readiness for surgery in IBD patients
Neil H. Hyman, MD
Watch Presentation  View Slides

4:20 pm  Management of intraoperative complications in IBD patients
Feza H. Remzi, MD
Watch Presentation  View Slides

4:40 pm  Management of acute postoperative complications in IBD patients
Philip R. Fleshner, MD
Watch Presentation  View Slides

5:00 pm  Management of chronic postoperative complications in IBD patients
Scott A. Strong, MD
Watch Presentation  View Slides

December 10, 2016

Session VIII-A: Advances in the Care of IBD Patients
Moderators: Millie Long, MD, MPH, Asher Kornbluth, MD

8:00 am  Travel alert: How can we prepare our patients for adventures abroad?
Corey A. Siegel, MD, MS
Watch Presentation  View Slides

8:20 am  Tight control and treat to target: How to assess the effectiveness of therapy
Jean-Frederic Colombel, MD
Watch Presentation  View Slides
8:40 am  Is there an optimal approach to prevent recurrence in post-operative Crohn's disease
*Miguel Regueiro, MD*

9:00 am  Approaches used to avoid and treat narcotic dependence
*Eva Szigethy, MD, PhD*

9:20 am  Challenges in clinical care: The volume of patients seen versus the value needed for each patient
*Thomas Ullman, MD*

Session IX-A: Endoscopic Approaches for the Diagnosis and Management of Challenging Problems (videos)
Moderators: Hans Herfarth, MD, PhD, Alan Moss, MD

10:30 am  How can we best determine endoscopic severity in ulcerative colitis and Crohn's disease (videos)?
*Francis Farraye, MD, MSc*

10:50 am  The endoscopic management of strictures in Crohn's disease (videos)
*Raymond K. Cross, MD*

11:10 am  Endoscopic evaluation and management of refractory fistulae and abscesses in Crohn's disease (videos)
*Bo Shen, MD*

11:30 am  How to identify dysplastic lesions in ulcerative colitis and Crohn's disease patients using endoscopy (videos)?
*Fernando S. Velayos, MD, MPH*

11:50 am  How to endoscopically resect visible lesions and polyps in ulcerative colitis and Crohn's disease patients (videos)
*Thomas Ullman, MD*

Session X-A: Case-based Clinical Breakout Sessions

2:00 & 3:00 pm  A. Treating the outpatient with moderate to severe Crohn's disease, who has developed a severe adverse reaction to a biologic: Case studies
*Kim L. Isaacs, MD, PhD, Asher Kornbluth, MD, James D. Lewis, MD, MSCE*
B. GI tract infections in IBD: Detection and treatment of clostridia difficile, CMV and enteric pathogens: Case studies
Ashwin N. Ananthakrishnan, MBBS, MD, MPH, Gil Y. Melmed, MD, MS, Alan Moss, MD

C. Challenges in decision making, for the surgical management of the severe ulcerative colitis patient refractory to medical therapy: Case studies
Meenakshi Bewtra, MD, PhD, MPH, Neil H. Hyman, MD, Scott A. Strong, MD

D. Treatment of IBD patients with liver disease: Case studies
Leonard K. Baidoo, MD, Russell Cohen, MD, Edward V. Loftus Jr., MD

E. Management of IBD patients with significant co-morbidities: Case studies
Hans Herfarth, MD, PhD, Peter D. Higgins, MD, PhD, MSc, Douglas C. Wolf, MD

Session XI-A: Selected Topics in IBD
Moderators: Francis Farraye, MD, MSc, Bo Shen, MD

4:00 pm  How should we manage and follow the low risk IBD patient with mild disease?
Hans Herfarth, MD, PhD

4:20 pm  Are there alternative, complementary therapies that our patients will benefit from?
Russell Cohen, MD

4:40 pm  What is the role of fecal microbiome transplants in IBD?
Alan Moss, MD

5:00 pm  What are the roles of environmental factors in the pathogenesis of IBD
Ashwin N. Ananthakrishnan, MBBS, MD, MPH
BASIC SCIENCE TRACK

December 9, 2016

Session IV-B: Advances in the Genetics of IBD
Moderators: Maria T. Abreu, MD, R. Balfour Sartor, MD

8:20 am  Mining Biobanks and electronic health records for IBD genetics insight
Judy H. Cho, MD

8:40 am  Crowd-sourcing in IBD research and clinical innovation
Jonathan Braun, MD, PhD

9:00 am  Genotype X phenotype associations: Progress at last
Dermot McGovern, MD, PhD

9:20 am  Early Onset IBD with rare causative variants: Understanding mucosal homeostasis and developing new therapeutic approaches
Scott B. Snapper, MD, PhD

Session V-B: Host-Microbiome Interactions in IBD
Moderators: Ken Cadwell, PhD, Shehzad Z. Sheikh, MD, PhD

10:30 am  Host-Microbial Co-Metabolism and its relevance to IBD
Gary D. Wu, MD

10:50 am  Lloyd Mayer Memorial Lecture: Identifying microbial targets in IBD
Maria T. Abreu, MD

11:10 am  Understanding pathogenic mechanisms of adherent/invasive E. coli strains
R. Balfour Sartor, MD

11:30 am  Identifying microbiota-derived metabolites that prevent colitogenic bacterial activities
Christian Jobin, PhD
11:50 am  Presentation of selected abstracts

Long ncRNA landscape in the ileum of treatment naïve early onset Crohn disease
Yael Haberman, et al., O-009

Microbial metabolites establish a gradient of protons, which mediate interkingdom host-microbiome cross-talk and maintain intestinal homeostasis via two proton-sensing GPRs
Ashfaqul Alam, et al., O-010

Session VI-B: Clarifying the Role of the Microbiome in IBD
Moderators: Jerrold R. Turner, MD, PhD, Christian Jobin, PhD

2:00 pm  How microbial imbalances and genetic susceptibility initiate intestinal inflammation
Ken Cadwell, PhD

2:20 pm  Role of microbial products in triggering and promoting IBD phenotypes
Thaddeus Steppenbeck, MD, PhD

2:40 pm  Microbial and microbiome biomarkers in risk and disease monitoring
Jonathan Braun, MD, PhD

3:00 pm  Progress toward discovering better commensal probiotic species
R. Balfour Sartor, MD

Session VII-B: Future Directions in Translational IBD Research
Moderators: Jonathan Braun, MD, PhD, Melissa Wong, PhD

4:00 pm  Identifying clinically relevant Crohn’s disease subsets by genomic analysis
Shehzad Z. Sheikh, MD, PhD

4:20 pm  Genetics to therapies: A critical assessment and future directions
Judy H. Cho, MD

4:40 pm  Can enhancement of autophagy be mined therapeutically?
Dana Philpott, PhD
5:00 pm  Pathogenesis-based approaches to sub-classify Crohn's disease and how this could improve the development of new IBD medications

*Thaddeus Stappenbeck, MD, PhD*

5:20 pm  Is the tight junction a realistic therapeutic target in IBD?

*Jerrold R. Turner, MD, PhD*

---

**December 10, 2016**

**Session VIII-B: Novel Models and Methods in IBD Research**

*Moderators: Fabio Cominelli, MD, PhD, Dana Philpott, PhD*

8:00 am  Mouse models of chronic intestinal inflammation: Similarities and differences to human IBD

*Jesus Rivera-Nieves, MD*

8:20 am  How humanized mouse models of IBD will lead to new insights in IBD pathogenesis and lead to new therapeutics

*Scott B. Snapper, MD, PhD*

8:40 am  Inflammation shapes microbial activities in the gut: Impact on carcinogenesis

*Christian Jobin, PhD*

9:00 am  Cancer stem cells in homeostatic and neoplastic tissues

*Melissa Wong, PhD*

9:20 am  Presentation of selected abstracts

- Low-dose IL-2 administration expands human regulatory T cells in patients with UC and humanized mice and protects against experimental colitis

*Jeremy Goettel, et al., O-011*

- IL-36 Signaling Controls the Induced Regulatory T Cell – TH9 Cell Balance and Gut Inflammation

*Akihito Harusato, et al., O-012*
## Session IX-B: From Mechanisms to Therapies

*Moderators: Judy H. Cho, MD, Gary D. Wu, MD*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am</td>
<td>The mechanistic role of NOD2 in Crohn's disease</td>
<td>Dana Philpott, PhD</td>
</tr>
<tr>
<td>10:50 am</td>
<td>T cell trafficking in IBD: Mechanisms, therapeutic targets and translational success</td>
<td>Jesus Rivera-Nieves, MD</td>
</tr>
<tr>
<td>11:10 am</td>
<td>The role of the virome and autophagy in animal models of Crohn's disease</td>
<td>Ken Cadwell, PhD</td>
</tr>
<tr>
<td>11:30 am</td>
<td>The role of T cells and immunoregulatory cytokines in mediating chronic intestinal inflammation in patients with Crohn's disease</td>
<td>Fabio Cominelli, MD, PhD</td>
</tr>
<tr>
<td>11:50 am</td>
<td>Where are we clinically with new biologics?</td>
<td>Maria T. Abreu, MD</td>
</tr>
</tbody>
</table>

## Session X-B: Characterizing the Role of the Intestinal Epithelium in the Pathogenesis of IBD

*Moderators: Jesus Rivera-Nieves, MD, Thaddeus Stappenbeck, MD, PhD*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Macrophage-epithelial fusion in Crohn’s disease and in cancer</td>
<td>Melissa Wong, PhD</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Dynamics of molecular oxygen at the intestinal mucosal interface</td>
<td>Gary D. Wu, MD</td>
</tr>
<tr>
<td>2:40 pm</td>
<td>Why is intestinal permeability increased in IBD?</td>
<td>Jerrold R. Turner, MD, PhD</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Presentation of selected abstracts</td>
<td></td>
</tr>
</tbody>
</table>

**Dietary emulsifiers directly impact the human gut microbiota increasing its pro-inflammatory potential and ability to induce intestinal inflammation**

*Benoit Chassaing, et al., O-013*
Bacterial sensor NOD2 deletion causes Th2-inflammatory bowel disease improvement without inducing acute metatranscriptomic dysbiosis in mice

*Alexander Rodriguez-Palacios, et al., O-014*

**Session XI-B: Roundtable Discussion of New Approaches to IBD Research**

**4:00 pm**  What new and exciting basic science approaches can now be explored to better understand the pathogenesis of IBD?
*Panelists: Judy H. Cho, MD, Fabio Cominelli, MD, PhD, Dana Philpott, PhD, Scott B. Snapper, MD, PhD, Melissa Wong, PhD*

**4:30 pm**  What new techniques should be used to better characterize the role of the microbiome in IBD?
*Panelists: Maria T. Abreu, MD, Christian Jobin, PhD, Ken Cadwell, PhD, R. Balfour Sartor, MD, Gary D. Wu, MD*

**5:00 pm**  How can we better translate basic observations into clinically relevant IBD research?
*Panelists: Jonathan Braun, MD, PhD, Dermot McGovern, MD, PhD, Jesus Rivera-Nieves, MD, Shehzad Z. Sheikh, MD, PhD, Thaddeus Stappenbeck, MD, PhD, Jerrold R. Turner, MD, PhD*
Session IV-C: Challenges in IBD Patient Management: Just Ask?

Moderators: Maureen Kelly, MS, Michele Rubin, APN, MSN, CNS, CGRN

8:00 am  Asking the right questions: Triaging the IBD patient
Susan Baldivieso, BSN, RN

8:30 am  Common challenges: Shared decision-making and patient engagement in treating IBD
Michele Rubin, APN, MSN, CNS, CGRN

9:00 am  Too shy to ask: Intimacy in IBD
Jenna Ottenheimer, MPH, PA-C

9:40 am  Presentation of selected abstracts
Impact of education on school nurses' knowledge of inflammatory bowel disease
Eun Soo Kim, et al., O-007

The Impact of A Nurse Navigator Program on Telephone Calls and Emergency Department Utilization Among IBD Patients
Anshika Kapur, et al., O-008

Session V-C: Expanding Roles for the IBD Nurse & Advanced Practitioner

Moderators: Maureen Kelly, MS, Michele Rubin, APN, MSN, CNS, CGRN

10:35 am  IBD nurse and advanced practitioner roles: Are you working to the full extent of your scope of practice?
Maureen Kelly, MS

11:00 am  Panel of speakers to discuss each of their RN/APN/PA roles
Panelists: Suzanne Baldivieso, BSN, RN, Maureen Kelly, MS, Michele Rubin, APN, MSN, CNS, CGRN, Jenna Ottenheimer, MPH, PA-C

11:30 am  Round table work groups with focused topics of discussion
Suzanne Baldivieso, BSN, RN, Maureen Kelly, MS, Jenna Ottenheimer, MPH, PA-C, Michele Rubin, APN, MSN, CNS, CGRN
12:00 pm  Reports from each round table
*Suzanne Baldivieso, BSN, RN, Maureen Kelly, MS, Jenna Ottenheimer, MPH, PA-C, Michele Rubin, APN, MSN, CNS, CGRN*

12:20 pm  Closing remarks and wrap up discussion of RN/APP roles in IBD patient care
*Maureen Kelly, MS, Michele Rubin, APN, MSN, CNS, CGRN*
Session VI-D: Progress in Pediatric IBD

Moderators: Sandra C. Kim, MD, Francisco A Sylvester, MD

2:00 pm  Clinical pediatric inflammatory bowel disease - the year in review (highlights from the literature)
Athos Bousvaros, MD, MPH

2:20 pm  Extraintestinal manifestations in pediatric IBD - a survey of conditions and treatments: Rheumatologic manifestations
Sandra Kim, MD

2:35 pm  Extraintestinal manifestations in pediatric IBD - a survey of conditions and treatments: Skin manifestations
Millie Long, MD, MPH

2:50 pm  Extraintestinal manifestations in pediatric IBD - a survey of conditions and treatments: Growth and bone development
Francisco A. Sylvester, MD

3:05 pm  Extraintestinal manifestations in pediatric IBD - a survey of conditions and treatments: Orofacial granulomatosis
Jeremy Adler, MD, MSc

3:20 pm  Extraintestinal manifestations in pediatric IBD - a survey of conditions and treatments: Pulmonary complications of IBD or treatment
Athos Bousvaros, MD, MPH

Session VII-D: Advances in Pediatric IBD

Moderators: Jeremy Adler, MD, MSc, Athos Bousvaros, MD, MPH

4:20 pm  Presentation of selected abstracts
Wael El-Matary, et al., O-006
Predicting a complicated course for children newly diagnosed with Crohn's disease: A multicenter inception cohort study
Subra Kugathasan, et al., O-002

The brain as extraintestinal IBD manifestation: Are brain and cognitive differences in pediatric Crohn’s disease associated with immune gene expression?
Christine Mrakotsky, et al., O-003

5:00 pm  Case discussions with expert 5 person panel
Moderators: Jeremy Adler, MD, MSc, Athos Bousvaros, MD, MPH
Panelists: Sandra C. Kim, MD, Millie D. Long, MD, MPH, Francisco A. Sylvester, MD

View Slides

December 10, 2016

Session VIII-D: Common Clinical Challenges in Pediatric IBD
Moderators: Athos Bousvaros, MD, MPH, Francisco A. Sylvester, MD

8:00 am  Assessing quality of life in our pediatric IBD patients
Jeremy Adler, MD
Watch Presentation  View Slides

8:20 am  How should methotrexate be used in our pediatric IBD patients?
Michael D. Kappelman, MD, MPH
Watch Presentation  View Slides

8:40 am  When can genetic testing be utilized in our IBD patients? Pediatric IBD patients?
Michael J. Rosen, MD, MSCI
Watch Presentation  View Slides

9:00 am  What are effective approaches to counsel our pediatric IBD patients, who are undergoing surgery for Crohn’s disease or ulcerative colitis?
Sandra Kim, MD
Watch Presentation  View Slides

Session IX-D: Targeting Therapies for the Pediatric Patient
Moderators: Jeremy Alder, MD, Athos Bousvaros, MD, MPH

10:00 am  Translational pediatric IBD: The year in review
Francisco A. Sylvester, MD
Watch Presentation  View Slides
10:30 am  Presentation of selected abstracts

Application of population pharmacokinetic modeling to develop individualized infliximab dosing strategies in pediatric Crohn’s disease
*Adam Frymoyer, et al., O-004*

Combination therapy with methotrexate does not change infliximab pharmacokinetics in children with inflammatory bowel disease
*Valentina Shakhnovich, et al., O-005*

A diagnostic approach of immune dysregulation on very early-onset IBD
*Judith Kelsen, et al., O-001*

11:10 am  Topics in ulcerative colitis

*Moderators: Marla Dubinsky, MD, Michael J. Rosen, MD, MSCI
Panellists: Athos Bouvaros, MD, MPH, Sandra Kim, MD, Francisco A. Sylvester, MD*

[View Slides](#)